<?xml version="1.0" encoding="UTF-8"?>
<compound>
  <id type="integer">4400</id>
  <title>T3D4346</title>
  <common-name>Beta-Alanine</common-name>
  <description>beta-Alanine is the only naturally occurring beta-amino acid - an amino acid in which the amino group is at the beta-position from the carboxylate group. It is formed in vivo by the degradation of dihydrouracil and carnosine. It is a component of the naturally occurring peptides carnosine and anserine and also of pantothenic acid (vitamin B-5), which itself is a component of coenzyme A. Under normal conditions, beta-alanine is metabolized into acetic acid. beta-Alanine can undergo a transanimation reaction with pyruvate to form malonate-semialdehyde and L-alanine. The malonate semialdehyde can then be converted into malonate via malonate-semialdehyde dehydrogenase. Malonate is then converted into malonyl-CoA and enter fatty acid biosynthesis. Since neuronal uptake and neuronal receptor sensitivity to beta-alanine have been demonstrated, beta-alanine may act as a false transmitter replacing gamma-aminobutyric acid. When present in sufficiently high levels, beta-alanine can act as a neurotoxin, a mitochondrial toxin, and a metabotoxin. A neurotoxin is a compound that damages the brain or nerve tissue. A mitochondrial toxin is a compound that damages mitochondria and reduces cellular respiration as well as oxidative phosphorylation. A metabotoxin is an endogenously produced metabolite that causes adverse health effects at chronically high levels. Chronically high levels of beta-alanine are associated with at least three inborn errors of metabolism, including GABA-transaminase deficiency, hyper-beta-alaninemia, and methylmalonate semialdehyde dehydrogenase deficiency. beta-Alanine is a central nervous system (CNS) depressant and is an inhibitor of GABA transaminase. The associated inhibition of GABA transaminase and displacement of GABA from CNS binding sites can also lead to GABAuria (high levels of GABA in the urine) and convulsions. In addition to its neurotoxicity, beta-alanine reduces cellular levels of taurine, which are required for normal respiratory chain function. Cellular taurine depletion is known to reduce respiratory function and elevate mitochondrial superoxide generation, which damages mitochondria and increases oxidative stress (PMID: 27023909). Individuals suffering from mitochondrial defects or mitochondrial toxicity typically develop neurotoxicity, hypotonia, respiratory distress, and cardiac failure. beta-Alanine is a biomarker for the consumption of meat, especially red meat.</description>
  <cas>107-95-9</cas>
  <pubchem-id>239</pubchem-id>
  <chemical-formula>C3H7NO2</chemical-formula>
  <weight nil="true"/>
  <appearance>White powder.</appearance>
  <melting-point>200°C</melting-point>
  <boiling-point></boiling-point>
  <density nil="true"/>
  <solubility>545.0 mg/mL</solubility>
  <specific-gravity nil="true"/>
  <flash-point nil="true"/>
  <vapour-pressure nil="true"/>
  <route-of-exposure nil="true"/>
  <target nil="true"/>
  <mechanism-of-toxicity nil="true"/>
  <metabolism nil="true"/>
  <toxicity nil="true"/>
  <lethaldose nil="true"/>
  <carcinogenicity>No indication of carcinogenicity to humans (not listed by IARC).</carcinogenicity>
  <use-source>This is an endogenously produced metabolite found in the human body. It is used in metabolic reactions, catabolic reactions or waste generation.</use-source>
  <min-risk-level nil="true"/>
  <health-effects>Chronically high levels of beta-alanine are associated with at least 2 inborn errors of metabolism including: GABA-Transaminase Deficiency and Methylmalonate Semialdehyde Dehydrogenase Deficiency.</health-effects>
  <symptoms nil="true"/>
  <treatment nil="true"/>
  <created-at type="dateTime">2014-08-29T06:30:45Z</created-at>
  <updated-at type="dateTime">2018-03-21T17:46:19Z</updated-at>
  <interacting-proteins nil="true"/>
  <wikipedia>beta-Alanine</wikipedia>
  <uniprot-id nil="true"/>
  <kegg-compound-id>C00099</kegg-compound-id>
  <omim-id nil="true"/>
  <chebi-id>16958</chebi-id>
  <biocyc-id>B-ALANINE</biocyc-id>
  <ctd-id nil="true"/>
  <stitch-id nil="true"/>
  <drugbank-id>DB03107</drugbank-id>
  <pdb-id>BAL</pdb-id>
  <actor-id nil="true"/>
  <organism nil="true"/>
  <export type="boolean">true</export>
  <metabolizing-proteins nil="true"/>
  <transporting-proteins nil="true"/>
  <moldb-smiles>NCCC(O)=O</moldb-smiles>
  <moldb-formula>C3H7NO2</moldb-formula>
  <moldb-inchi>InChI=1S/C3H7NO2/c4-2-1-3(5)6/h1-2,4H2,(H,5,6)</moldb-inchi>
  <moldb-inchikey>InChIKey=UCMIRNVEIXFBKS-UHFFFAOYSA-N</moldb-inchikey>
  <moldb-average-mass type="decimal">89.0932</moldb-average-mass>
  <moldb-mono-mass type="decimal">89.047678473</moldb-mono-mass>
  <origin>Endogenous</origin>
  <state>Solid</state>
  <logp>-3.05</logp>
  <hmdb-id>HMDB00056</hmdb-id>
  <chembl-id>CHEMBL297569</chembl-id>
  <chemspider-id>234</chemspider-id>
  <structure-image-file-name nil="true"/>
  <structure-image-content-type nil="true"/>
  <structure-image-file-size type="integer" nil="true"/>
  <structure-image-updated-at type="dateTime" nil="true"/>
  <biodb-id nil="true"/>
  <synthesis-reference>&lt;p&gt;Erwin Grill, Ernst-Ludwig Winnacker, Meinhart H. Zenk, &amp;#8220;Cysteine-rich peptides having gamma-glutamic acid and beta-alanine units, a process for their preparation and their use.&amp;#8221; U.S. Patent US4883861, issued March, 1978.&lt;/p&gt;</synthesis-reference>
  <structure-image-caption nil="true"/>
</compound>
